Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Barnidipine hydrochloride (YM-09730-5 hydrochloride) 是一种二氢吡啶类钙通道阻滞剂,对 CaA 受体具有选择性作用。它是一种抗高血压药物,通过减少其血管扩张作用继发的外周血管阻力起作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 215 | 现货 | ||
5 mg | ¥ 489 | 现货 | ||
10 mg | ¥ 788 | 现货 | ||
25 mg | ¥ 975 | 现货 | ||
50 mg | ¥ 1,160 | 现货 | ||
100 mg | ¥ 1,680 | 现货 | ||
200 mg | ¥ 2,530 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 867 | 现货 |
产品描述 | Barnidipine hydrochloride (YM-09730-5 hydrochloride) is a dihydropyridine calcium channel blocker that has an IC50 value of 0.35 nM in potassium-induced tonic contraction of pig coronary artery |
靶点活性 | [3H]-Initrendipine:0.21 nmol/l (Ki) |
体内活性 | Barnidipine demonstrates antihypertensive activity by reducing peripheral vascular resistance. It decreases blood pressure in spontaneously hypertensive rats when administered orally at 1 and 3 mg/kg per day[1]. Formulations containing barnidipine have been used as a treatment for hypertension. In obstructive sleep apnea patients with non-dipper pattern hypertension, barnidipine reduced mean nighttime systolic and diastolic arterial blood pressure[2]. |
动物实验 | Forty-one patients (mean age 69 ± 17 years, 18 females) with previously diagnosed OSA (by reduced channel home-based polysomnography) who were not being treated with continuous positive airway pressure (CPAP) because of contraindications or because of patient intolerance or rejection were evaluated. Non-dipper status was defined as the presence of a nighttime fall in systolic blood pressure (BP) which was < 10% that of daytime systolic BP as observed in a previous ambulatory blood pressure (ABP) monitoring. OSA was defined according to the presence of 5 or more episodes per hour of apnoea, hypopnoea or arousal due to respiratory effort. The reproducibility of non-dipping status was confirmed through a second 24-h ABP monitoring performed at baseline. On top of the previous stable treatment regimen (which excluded calcium-channel blockers), a 10 mg dosing of barnidipine hydrochloride at bedtime was added to all subjects during a 12-week period[2]. |
别名 | 盐酸巴尼地平, YM-09730-5 hydrochloride, Mepirodipine (hydrochloride) |
分子量 | 528 |
分子式 | C27H30ClN3O6 |
CAS No. | 104757-53-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (473.48 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8939 mL | 9.4697 mL | 18.9394 mL | 47.3485 mL |
5 mM | 0.3788 mL | 1.8939 mL | 3.7879 mL | 9.4697 mL | |
10 mM | 0.1894 mL | 0.947 mL | 1.8939 mL | 4.7348 mL | |
20 mM | 0.0947 mL | 0.4735 mL | 0.947 mL | 2.3674 mL | |
50 mM | 0.0379 mL | 0.1894 mL | 0.3788 mL | 0.947 mL | |
100 mM | 0.0189 mL | 0.0947 mL | 0.1894 mL | 0.4735 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Barnidipine hydrochloride 104757-53-1 Membrane transporter/Ion channel Metabolism Calcium Channel Mepirodipine 盐酸巴尼地平 Ca2+ channels inhibit Barnidipine YM-09730-5 hydrochloride Inhibitor Ca channels Barnidipine Hydrochloride Mepirodipine (hydrochloride) YM-09730-5 Hydrochloride inhibitor